Biolife Solutions Stock Analysis
| BLFS Stock | USD 25.07 0.27 1.07% |
BioLife Solutions is undervalued with Real Value of 28.92 and Target Price of 32.1. The main objective of BioLife Solutions stock analysis is to determine its intrinsic value, which is an estimate of what BioLife Solutions is worth, separate from its market price. There are two main types of BioLife Solutions' stock analysis: fundamental analysis and technical analysis.
The BioLife Solutions stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. BioLife Solutions is usually not traded on Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day. BioLife Stock trading window is adjusted to America/New York timezone.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioLife Solutions. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. BioLife Stock Analysis Notes
About 98.0% of the company shares are held by institutions such as insurance companies. The book value of BioLife Solutions was currently reported as 7.38. The company has Price/Earnings (P/E) ratio of 173.59. BioLife Solutions recorded a loss per share of 0.38. The entity had not issued any dividends in recent years. The firm had 1:14 split on the 29th of January 2014. BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington. Biolife Solutions operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 432 people. For more info on BioLife Solutions please contact Michael Rice at 425 402 1400 or go to https://www.biolifesolutions.com.BioLife Solutions Investment Alerts
| The company reported the previous year's revenue of 82.25 M. Net Loss for the year was (20.18 M) with profit before overhead, payroll, taxes, and interest of 64.37 M. | |
| BioLife Solutions has a frail financial position based on the latest SEC disclosures | |
| Over 98.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from thelincolnianonline.com: BioLife Solutions Insider Karen Foster Sells 519 Shares of Stock |
BioLife Solutions Upcoming and Recent Events
| 21st of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 21st of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
BioLife Largest EPS Surprises
Earnings surprises can significantly impact BioLife Solutions' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-05-13 | 2021-03-31 | -0.04 | -0.03 | 0.01 | 25 | ||
2020-05-14 | 2020-03-31 | -0.02 | -0.01 | 0.01 | 50 | ||
2019-05-09 | 2019-03-31 | 0.04 | 0.03 | -0.01 | 25 |
BioLife Solutions Environmental, Social, and Governance (ESG) Scores
BioLife Solutions' ESG score is a quantitative measure that evaluates BioLife Solutions' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of BioLife Solutions' operations that may have significant financial implications and affect BioLife Solutions' stock price as well as guide investors towards more socially responsible investments.
BioLife Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2025-06-30 | 921.1 K | Palisade Capital Management Llc | 2025-06-30 | 919.5 K | Geneva Capital Management | 2025-06-30 | 901.8 K | Royal Bank Of Canada | 2025-06-30 | 791.3 K | Ing Investment Management Llc | 2025-06-30 | 720.1 K | Cramer Rosenthal Mcglynn Llc | 2025-06-30 | 704.2 K | Bank Of America Corp | 2025-06-30 | 671.7 K | Granahan Investment Management Inc.. | 2025-06-30 | 643.2 K | Mutual Of America Capital Management Llc | 2025-06-30 | 638.4 K | Casdin Capital, Llc | 2025-06-30 | 7.7 M | Blackrock Inc | 2025-06-30 | 5.5 M |
BioLife Market Capitalization
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.21 B.BioLife Profitablity
The company has Profit Margin (PM) of (0.03) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average.| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.11) | (0.12) | |
| Return On Capital Employed | (0.02) | (0.02) | |
| Return On Assets | (0.05) | (0.05) | |
| Return On Equity | (0.06) | (0.06) |
Management Efficiency
Return On Tangible Assets is likely to drop to -0.12 in 2025. Return On Capital Employed is likely to drop to -0.02 in 2025. At this time, BioLife Solutions' Fixed Asset Turnover is comparatively stable compared to the past year. BioLife Solutions' management efficiency ratios could be used to measure how well BioLife Solutions manages its routine affairs as well as how well it operates its assets and liabilities.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 7.57 | 7.95 | |
| Tangible Book Value Per Share | 2.76 | 2.90 | |
| Enterprise Value Over EBITDA | 738.05 | 774.95 | |
| Price Book Value Ratio | 3.43 | 3.26 | |
| Enterprise Value Multiple | 738.05 | 774.95 | |
| Price Fair Value | 3.43 | 3.26 | |
| Enterprise Value | 1.1 B | 1.2 B |
The strategic decisions made by BioLife Solutions management significantly impact its financial stability and market performance. Evaluating these factors helps determine whether the stock is a worthwhile investment.
Technical Drivers
As of the 21st of December, BioLife Solutions shows the Standard Deviation of 2.36, risk adjusted performance of (0.01), and Mean Deviation of 1.74. BioLife Solutions technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm BioLife Solutions variance and potential upside to decide if BioLife Solutions is priced correctly, providing market reflects its regular price of 25.07 per share. Given that BioLife Solutions has information ratio of (0.05), we suggest you to validate BioLife Solutions's prevailing market performance to make sure the company can sustain itself at a future point.BioLife Solutions Price Movement Analysis
The output start index for this execution was thirty-two with a total number of output elements of twenty-nine. The MESA Adaptive Moving Average indicator adapts to BioLife Solutions price movement based on the rate change of phase as measured by the Hilbert Transform Discriminator.
BioLife Solutions Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific BioLife Solutions insiders, such as employees or executives, is commonly permitted as long as it does not rely on BioLife Solutions' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases BioLife Solutions insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
BioLife Solutions Outstanding Bonds
BioLife Solutions issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. BioLife Solutions uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most BioLife bonds can be classified according to their maturity, which is the date when BioLife Solutions has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| BIOGEN INC 52 Corp BondUS09062XAD57 | View | |
| BIOGEN INC Corp BondUS09062XAG88 | View | |
| BIOGEN INC Corp BondUS09062XAH61 | View | |
| BIIB 325 15 FEB 51 Corp BondUS09062XAK90 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
BioLife Solutions Predictive Daily Indicators
BioLife Solutions intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of BioLife Solutions stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
BioLife Solutions Corporate Filings
F4 | 17th of December 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 5th of December 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 28th of November 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 21st of November 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 17th of November 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 13th of November 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 6th of November 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 28th of October 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
BioLife Solutions Forecast Models
BioLife Solutions' time-series forecasting models are one of many BioLife Solutions' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary BioLife Solutions' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About BioLife Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how BioLife Solutions prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling BioLife shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as BioLife Solutions. By using and applying BioLife Stock analysis, traders can create a robust methodology for identifying BioLife entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (0.14) | (0.15) | |
| Operating Profit Margin | (0.09) | (0.09) | |
| Net Loss | (0.25) | (0.26) | |
| Gross Profit Margin | 0.65 | 0.42 |
Current BioLife Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. BioLife analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. BioLife analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 32.1 | Strong Buy | 9 | Odds |
Most BioLife analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand BioLife stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of BioLife Solutions, talking to its executives and customers, or listening to BioLife conference calls.
BioLife Stock Analysis Indicators
BioLife Solutions stock analysis indicators help investors evaluate how BioLife Solutions stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading BioLife Solutions shares will generate the highest return on investment. By understating and applying BioLife Solutions stock analysis, traders can identify BioLife Solutions position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 35.4 M | |
| Long Term Debt | 5 M | |
| Common Stock Shares Outstanding | 46.1 M | |
| Total Stockholder Equity | 348.9 M | |
| Total Cashflows From Investing Activities | 58.3 M | |
| Tax Provision | -38 K | |
| Quarterly Earnings Growth Y O Y | 6.4 | |
| Property Plant And Equipment Net | 16.8 M | |
| Cash And Short Term Investments | 104.6 M | |
| Cash | 95.4 M | |
| Accounts Payable | 3.6 M | |
| Net Debt | -65.2 M | |
| 50 Day M A | 26.311 | |
| Total Current Liabilities | 32.7 M | |
| Other Operating Expenses | 89.4 M | |
| Non Current Assets Total | 250.7 M | |
| Forward Price Earnings | 1000 | |
| Non Currrent Assets Other | 6.5 M | |
| Stock Based Compensation | 30.9 M |
Additional Tools for BioLife Stock Analysis
When running BioLife Solutions' price analysis, check to measure BioLife Solutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLife Solutions is operating at the current time. Most of BioLife Solutions' value examination focuses on studying past and present price action to predict the probability of BioLife Solutions' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLife Solutions' price. Additionally, you may evaluate how the addition of BioLife Solutions to your portfolios can decrease your overall portfolio volatility.